Zeus Scientific

Executive Summary

Zeus Scientific is a US-based, family-owned diagnostics company with over 40 years of expertise in autoimmune and infectious disease testing. The company offers a comprehensive menu of assays across ELISA, multiplex bead array (AtheNA Multi-Lyte), and immunofluorescence (IFA) platforms, anchored by its flagship ZEUS dIFine 30 System for automated IFA processing and digital imaging. With a focus on flexibility and laboratory efficiency, Zeus provides contract manufacturing and commercialization services, positioning itself as a versatile partner for clinical laboratories. The company's deep experience in autoimmune diagnostics, combined with its proprietary automation technology, gives it a competitive edge in a market driven by increasing demand for chronic disease management and point-of-care solutions. While privately held with limited financial disclosure, Zeus Scientific's sustained operations and innovation suggest a stable market niche.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for new multiplex autoimmune assay panel70% success
• Q3 2026Launch of enhanced ZEUS dIFine 30 System with AI-based image analysis60% success
• Q4 2026Strategic distribution partnership for European market expansion50% success